TABLE 2.

Nature of treatment change by first and second line of treatment (full analysis set population)

Treatment change, n (%)		Primary type of treatment change, a n (%)		Primary reason for treatment change, a n (%)
First line of treatment
No	583 (50.7)	Discontinuation of biologics	30 (5.3)	Adverse events	38 (6.7)
Yes	566 (49.3)	Dose change	45 (8.0)	Flare in comorbidity	9 (1.6)
		Interval change	250 (44.2)	Lack of efficacy	380 (67.3)
		Other	35 (6.2)	Other	53 (9.4)
		Switching to another biologic	193 (34.1)	Patient lost to follow‐up	2 (0.4)
		Unknown	13 (2.3)	Patient request	17 (3.0)
				Safety concerns	5 (0.9)
				Unknown	61 (10.8)
Second line of treatment
No	127 (40.2)	Discontinuation of biologics	17 (9.0)	Adverse events	12 (6.3)
Yes	189 (59.8)	Dose change	13 (6.9)	Flare in comorbidity	2 (1.1)
		Interval change	79 (41.8)	Lack of efficacy	128 (67.7)
		Other	8 (4.2)	Other	16 (8.5)
		Switching to another biologic	71 (37.6)	Patient lost to follow‐up	0 (0)
		Unknown	1 (0.5)	Patient request	11 (5.8)
				Safety concerns	1 (0.5)
				Unknown	19 (10.0)

Changes included switching, discontinuation, dose escalation, and interval change.

^a Percentages of “yes”, patients who had treatment change.